<DOC>
	<DOCNO>NCT00003615</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins denileukin diftitox locate cancer cell kill without harm normal cell . This may effective treatment non-Hodgkin 's lymphoma . PURPOSE : Phase II trial study effectiveness denileukin diftitox treat patient non-Hodgkin 's lymphoma respond previous treatment .</brief_summary>
	<brief_title>Denileukin Diftitox Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient previously treat stage I , II , III , IV low- intermediate-grade B-cell non-Hodgkin 's lymphoma treat denileukin diftitox . II . Determine time progression , duration remission , time treatment failure patient treatment therapy . III . Determine toxicity therapy patient . IV . Correlate result inteleukin-2 receptor assay treatment outcome patient . OUTLINE : Patients stratify accord interleukin-2 receptor classification ( positive v negative ) . Patients receive immunotoxin therapy denileukin diftitox IV 15-60 minute day 1-5 . Treatment repeat every 21 day 2-6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 33 patient accrue interleukin-2 ( IL-2 ) receptor-positive stratum total 11-44 patient accrue IL-2 receptor-negative stratum .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage I , II , III , IV low intermediategrade Bcell nonHodgkin 's lymphoma Small lymphocytic Follicular small cleave cell Follicular mix cell Follicular large cell Marginal Diffuse large Bcell Lymphoplasmacytoid Patients small lymphocytic lymphoma must absolute lymphocyte count le 10,000/mm3 At least one bidimensionally measurable site At least 1.5 cm great dimension Not field prior radiotherapy Progressive disease least one prior treatment regimen lymphoma A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute neutrophil count least 1000/mm3 Platelet count least 50,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 2 time ULN Albumin great 3.0 g/dL No hepatitis B C infection Renal : Creatinine great ULN Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No active infection require antiinfective therapy No prior invasive malignancy within past 5 year , except : Curatively treat basal cell squamous cell skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Prior stem cell transplantation allow At least 4 week since prior biologic therapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 4 week since prior endocrine therapy No concurrent hormonal therapy ( except contraceptive replacement steroid ) No concurrent corticosteroid Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy localize disease No concurrent radiotherapy Surgery : Not specify Other : No concurrent experimental medication ( include approve drug test investigational setting )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>